| Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2 … U Platzbecker, JM Middeke, K Sockel, R Herbst, D Wolf, CD Baldus, ... The Lancet Oncology 19 (12), 1668-1679, 2018 | 284 | 2018 |
| Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease R Zeiser, N Polverelli, R Ram, SK Hashmi, R Chakraverty, JM Middeke, ... New England Journal of Medicine 385 (3), 228-238, 2021 | 268 | 2021 |
| Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease A Theil, S Tuve, U Oelschlägel, A Maiwald, D Döhler, D Oßmann, ... Cytotherapy 17 (4), 473-486, 2015 | 206 | 2015 |
| Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase N Alakel, JM Middeke, J Schetelig, M Bornhäuser OncoTargets and therapy, 597-605, 2017 | 108 | 2017 |
| TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML J Vadakekolathu, C Lai, S Reeder, SE Church, T Hood, A Lourdusamy, ... Blood advances 4 (20), 5011-5024, 2020 | 107 | 2020 |
| Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? C Röllig, M Kramer, C Schliemann, JH Mikesch, B Steffen, A Krämer, ... Blood, The Journal of the American Society of Hematology 136 (7), 823-830, 2020 | 99 | 2020 |
| Karyotype complexity and prognosis in acute myeloid leukemia F Stölzel, B Mohr, M Kramer, U Oelschlägel, T Bochtler, WE Berdel, ... Blood cancer journal 6 (1), e386-e386, 2016 | 99 | 2016 |
| CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome F Taube, JA Georgi, M Kramer, S Stasik, JM Middeke, C Röllig, U Krug, ... Blood, The Journal of the American Society of Hematology 139 (1), 87-103, 2022 | 95 | 2022 |
| TP53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation JM Middeke, S Herold, E Rücker‐Braun, WE Berdel, M Stelljes, ... British journal of haematology 172 (6), 914-922, 2016 | 93 | 2016 |
| MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation M Wermke, A Schmidt, JM Middeke, K Sockel, M von Bonin, ... Clinical Cancer Research 18 (23), 6460-6468, 2012 | 92 | 2012 |
| Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML M Wermke, S Kraus, A Ehninger, RC Bargou, ME Goebeler, JM Middeke, ... Blood, The Journal of the American Society of Hematology 137 (22), 3145-3148, 2021 | 90 | 2021 |
| Outcome of patients with abnl (17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation JM Middeke, M Fang, JJ Cornelissen, B Mohr, FR Appelbaum, M Stadler, ... Blood, The Journal of the American Society of Hematology 123 (19), 2960-2967, 2014 | 75 | 2014 |
| Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: Negative impact of abnl (17p) and− 5/5q− JM Middeke, D Beelen, M Stadler, G Göhring, B Schlegelberger, ... Blood, The Journal of the American Society of Hematology 120 (12), 2521-2528, 2012 | 71 | 2012 |
| Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology S Koristka, A Kegler, R Bergmann, C Arndt, A Feldmann, S Albert, ... Journal of Autoimmunity 90, 116-131, 2018 | 69 | 2018 |
| Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas N Liebers, J Duell, D Fitzgerald, A Kerkhoff, D Noerenberg, E Kaebisch, ... Blood advances 5 (13), 2707-2716, 2021 | 68 | 2021 |
| The clinical mutatome of core binding factor leukemia S Opatz, SA Bamopoulos, KH Metzeler, T Herold, B Ksienzyk, K Bräundl, ... Leukemia 34 (6), 1553-1562, 2020 | 67 | 2020 |
| ZBTB7A mutations in acute myeloid leukaemia with t (8; 21) translocation L Hartmann, S Dutta, S Opatz, S Vosberg, K Reiter, G Leubolt, ... Nature communications 7 (1), 11733, 2016 | 60 | 2016 |
| Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects JN Eckardt, M Bornhäuser, K Wendt, JM Middeke Blood Advances 4 (23), 6077-6085, 2020 | 53 | 2020 |
| Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia R Lal, K Lind, E Heitzer, P Ulz, K Aubell, K Kashofer, JM Middeke, ... Blood, The Journal of the American Society of Hematology 129 (18), 2587-2591, 2017 | 53 | 2017 |
| Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears JN Eckardt, JM Middeke, S Riechert, T Schmittmann, AS Sulaiman, ... Leukemia 36 (1), 111-118, 2022 | 44 | 2022 |
